Search
Cariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigational[A247100] It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. … Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary.
Categories: Dopamine D2/D3 receptor modulatorsDaridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigationalConventional treatments for insomnia include drugs targeting gamma-aminobutyric acid type-A (GABA-A), serotonin, histamine, or melatonin receptors; however, undesirable side effects are frequently reported … Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia.
Grazoprevir
go.drugbank.com/drugs/DB11575ApprovedGrazoprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. … in the NS5A protein and previous treatment failure with [DB00811], [DB00008], [DB00022], or other NS3/4A inhibitors like [DB08873], [DB06290], or [DB05521] [FDA Label].
Categories: NS3/4A Protease Inhibitors, HCV NS3/4A Protease InhibitorsPalbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigational[L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male … It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-oneGivinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigational[L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD). … Givinostat is a small molecule histone deacetylase (HDAC) inhibitor.
Pheniramine
go.drugbank.com/drugs/DB01620ApprovedPheniramine is a first-generation antihistamine in the alkylamine class, similar to [brompheniramine] and [chlorpheniramine].
Mixtures: Alahist D, Rhume Et De LA Grippe (extra-fort)Lanolin
go.drugbank.com/drugs/DB11112ApprovedLanolin is a yellow fat obtained from sheep's wool. It is used as an emollient, cosmetic, and pharmaceutic aid [L2580].
Mixtures: Blistex European Formula, Dg Baby Vitamins A and DCategories: Compounds used in a research, industrial, or household settingOmacetaxine mepesuccinate
go.drugbank.com/drugs/DB04865ApprovedInvestigationalWithdrawnThen in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. … Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies
Synonyms: mepesuccinato de omacetaxina, 1-[(1S,3aR,14bS)-2-Methoxy-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[a][1,3]dioxolo[4,5-H]pyrrolo[2,1-b][3]benzazepin-1-yl] 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioateLutetium Lu-177 vipivotide tetraxetan
go.drugbank.com/drugs/DB16778ApprovedInvestigational[L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate … It consists of a radionuclide, [lutetium Lu-177], linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer.
Categories: Compounds used in a research, industrial, or household settingLinerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigational[A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC). … Linerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT).